EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 821 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Program Helps Medically Underserved, Minority Cancer Survivors Be More Active July 3, 2024 New Combination of Old Drugs Improves Survival in Patients with Prostate... September 19, 2021 A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... October 12, 2021 Cancer in My Community: Overcoming Delays in Care for Children With... July 6, 2023 Load more HOT NEWS ΣΤΑΤΙΣΤΙΚΑ Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... Healthy and Delicious Figs ESMO Asia Virtual Congress 2020, 20-22 November
